English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

One hundred twenty six patients with subarachnoid hemorrhage due to ruptured intracranial aneurysm were admitted to our service between June 1988 and November 1989. Of these, 79 patients were treated with sodium ozagrel, thromboxane A9 synthetase inhibitor, or nizofenone, cerebral protector for ischemic cerebral damage. The effects were evaluated by the outcome of patients, incidence of symptomatic vasospasm and fatal vasospasm. Sodium ozagrel improved the outcome of patients and reduced the incidence of fatal vasospasm; however, it did not reduce the incidence of symptomatic vasospasm. Nizofenone was effective as well, but less so than sodium ozagrel. These results suggested that both drugs were effective in the treatment of delayed ischemic neurological deficits (DIND) due to cerebral vasospasm after subarachnoid hemorrhage.

Effect of Sodium Ozagrel and Nizofenone in the Treatment of Patients with Cerebral Vasospasm after Subarachnoid Hemorrhage